Aarti Drugs’ API business gains as pharma firms diversify raw material sourcing from China – Moneycontrol

1 min read
Company’s stock among those that gained substantially during COVID-19 days. Drug maker planning contract manufacturing of specialty products. Other Indian pharma companies also benefit as buyers, both domestic and global, scout for non-Chinese suppliers of ra…
Aarti Drugs’ API business gains as pharma firms diversify raw material sourcing from China – Moneycontrol

Company’s stock among those that gained substantially during COVID-19 days. Drug maker planning contract manufacturing of specialty products. Other Indian pharma companies also benefit as buyers, both domestic and global, scout for non-Chinese suppliers of ra…
Read More

Leave a Reply

Your email address will not be published. Required fields are marked *